India's drug regulator has banned the manufacture and sale of 35 fixed dose combinations (FDCs), citing concerns over patient safety and potential adverse reactions. The Drug Controller General of India (DCGI) has directed state drug controllers to review approval processes for combination drugs ..read more

Donald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40% of US generic imports. While the move aims to lower drug costs for Americans, potential tariffs on pharma imports create uncertainty ..read more

India's drug regulator, CDSCO, has ordered a halt to the production, sale, and distribution of 35 fixed-dose combination (FDC) drugs due to safety concerns. These drugs, including pain relievers and diabetes medications, lacked proper evaluation before approval. The CDSCO has directed state and Union territory regulators to reassess approval procedures, ensuring adherence to the Drugs and Cosmetics Act ..read more

India is experiencing a surge in demand for dehydration-preventing drinks due to the intense heatwave. Electral sales have jumped 27% in March, leading the oral electrolyte market's growth. Doctors are reporting an increase in digestive disorder cases, further fueling the need for rehydration solutions as temperatures rise and waterborne diseases become more prevalent ..read more

AstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib (Lynparza) 100mg and 150mg in India, citing commercial reasons. The company clarified that the drug was never marketed in India since receiving approval in November 2023 and that the decision is unrelated to safety or efficacy concerns ..read more

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has been reduced to ₹2,000 crore due to declining sales and government price cuts. Despite newer insulin options, Lantus remains a market leader in India's growing diabetes market ..read more

India's pharmaceutical industry is bracing for potential disruptions due to US tariffs on Chinese goods. Experts warn that China may increase prices for key pharmaceutical ingredients exported to India to offset tariff costs. With India heavily reliant on China for APIs and intermediates, this could lead to higher medicine production costs ..read more

Dr. Reddy's Laboratories has refuted a media report alleging a significant workforce cost reduction initiative. The report claimed the company aimed to cut manpower expenses by 25%, prompting high-salaried employees, including those earning over ₹1 crore annually, to resign. Voluntary retirement was also reportedly offered to R&D employees aged 50-55, but the company denies these claims ..read more

Dr. Reddy's Laboratories is implementing cost-cutting measures, aiming to reduce manpower expenses by 25%. High-salaried employees, including those earning over ₹1 crore annually, are being asked to resign. The R&D division is offering voluntary retirement to employees aged 50–55. Some divisions, like digital therapeutics, may face shutdowns or downsizing, impacting 300–400 employees ..read more

Glenmark, Sun Pharma, and Zydus are recalling various products in the US due to manufacturing issues and CGMP deviations, according to the USFDA. Glenmark is recalling over 25 products, while Sun Pharma is recalling Gabapentin capsules due to cross-contamination. Zydus is recalling chlorproMAZINE Hydrochloride Tablets due to an impurity exceeding the recommended limit ..read more